Trevi Therapeutics (TRVI) Cash from Investing Activities (2018 - 2026)

Trevi Therapeutics' Cash from Investing Activities history runs 8 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 270.49% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at -$67.2 million (down 187.29% YoY), while the FY2025 annual figure was -$94.1 million, down 337.14% from the prior year.
• Cash from Investing Activities was $17.0 million for Q1 2026 at Trevi Therapeutics, up from -$30.6 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $19.6 million in Q2 2023 to a low of -$50.9 million in Q3 2025.
• Historically, Cash from Investing Activities has averaged -$6.2 million across 5 years, with a median of -$2.6 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Cash from Investing Activities surged 470.76% in 2023, then tumbled 764.38% in 2025.
• A 5-year view of Cash from Investing Activities shows it stood at -$48.3 million in 2022, then surged by 126.59% to $12.8 million in 2023, then sank by 285.85% to -$23.9 million in 2024, then retreated by 28.22% to -$30.6 million in 2025, then jumped by 155.43% to $17.0 million in 2026.
• The last three Cash from Investing Activities figures came in at $17.0 million (Q1 2026), -$30.6 million (Q4 2025), and -$50.9 million (Q3 2025), per Business Quant data.